Soluble CD146 boosts therapeutic effect of endothelial progenitors through proteolytic processing of short CD146 isoform

International audienceEndothelial colony-forming cells (ECFC) constitute an endothelial progenitor fraction with a promising interest for the treatment of ischaemic cardiovascular diseases. As soluble CD146 (sCD146) is a new factor promoting angiogenesis, we examined whether sCD146 priming could improve the therapeutic potential of ECFC and defined the involved mechanism.We investigated the effects of sCD146 priming on regenerative properties of ECFC in vivo. In a mouse model of hindlimb ischaemia, the homing of radiolabelled cells to ischaemic tissue was assessed by SPECT-CT imaging. Soluble CD146 priming did not modify the number of engrafted ECFC but improved their survival capacity, leading to an enhanced revascularization. The mechanism of action of sCD146 on ECFC was studied in vitro. We showed that sCD146 acts in ECFC through a signalosome, located in lipid rafts, containing angiomotin, the short isoform of CD146 (shCD146), VEGFR1, VEGFR2, and presenilin-1. Soluble CD146 induced a sequential proteolytic cleavage of shCD146, with an extracellular shedding followed by an intramembrane cleavage mediated by matrix metalloprotease (MMP)/ADAM and presenilin-1, respectively. The generated intracellular part of shCD146 was directed towards the nucleus where it associated with the transcription factor CSL and modulated the transcription of genes involved in cell survival (FADD, Bcl-xl) and angiogenesis (eNOS). This effect was dependent on both VEGFR1 and VEGFR2, which were rapidly phosphorylated by sCD146.These findings establish that activation of the proteolytic processing of shCD146, in particular by sCD146, constitutes a promising pathway to improve endothelial progenitors' regenerative properties for the treatment of cardiovascular diseases

CONCERTO at APEX: Installation and Technical Commissioning

International audienceWe describe the deployment and first tests on sky of CONCERTO, a large field-of-view (18.6 arc-min) spectral-imaging instrument. The instrument operates in the range 130-310 GHz from the APEX 12-metres telescope located at 5100 m a.s.l. on the Chajnantor plateau. Spectra with R=ν /Δ ν ≤300 are obtained using a fast (2.5 Hz mechanical frequency) Fourier Transform Spectrometer (FTS), coupled to a continuous dilution cryostat with a base temperature of 60 mK. Two 2152-pixels arrays of Lumped Element Kinetic Inductance Detectors (LEKID) are installed in the cryostat that also contains the cold optics and the front-end electronics. CONCERTO, installed in April 2021, generates more than 20k spectra per second during observations. We describe the final development phases, the installation and the first results obtained on sky

Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study (Internal and Emergency Medicine, (2018), 13, 5, (651-660), 10.1007/s11739-018-1835-9)

In the original publication, one of the ARAPACIS collaborators Dr. “Leonardo Di Gennaro” name has been erroneously mentioned as “Leonardo De Gennaro”